Item 7.01 Regulation FD Disclosure.

On August 4, 2022, Marker Therapeutics, Inc. issued a press release (the "Press Release") announcing that the FDA cleared the Company's Investigational New Drug application for MT-601. A copy of this Press Release is furnished herewith as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01 of the Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.





(d)  Exhibits



Exhibit No.   Description
  99.1          Press Release, dated August 4, 2022
              The cover page from Marker Therapeutics, Inc.'s Form 8-K filed on
104           August 4, 2022, formatted in Inline XBRL

© Edgar Online, source Glimpses